BIOMAT Database Logo BIOMAT Database Logo

Aminoglycoside nephrotoxicity: comparative assessment in critically ill patients. 1979

M E Plaut, and J J Schentag, and W J Jusko

In a prospective trial to determine the incidence of nephrotoxicity with each of three aminoglycoside antibiotics, adults in intensive care units with presumed or proven bacterial infections were treated with intravenous gentamicin, tobramycin, or amikacin. Treatment groups were similar with respect to age, other medical disorders, type of infection, duration of aminoglycoside therapy, additional antibiotics used, other drugs prescribed (notably diuretics and corticosteroids), and rate of superinfection. Nephrotoxicity occurred with gentamicin during 44/121 (36.3%) treatment courses, with tobramycin during 21/92 (22.8%) courses, and with amikacin during 4/16 (25.0%) courses. Although frequent, nephrotoxicity reversed after treatment stopped. Tobramycin nephrotoxicity occurred significantly less often than did gentamicin nephrotoxicity (p less than 0.05). The relative safety of tobramycin may result from lower tissue accumulation during therapy.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003422 Critical Care Health care provided to a critically ill patient during a medical emergency or crisis. Intensive Care,Intensive Care, Surgical,Surgical Intensive Care,Care, Critical,Care, Intensive,Care, Surgical Intensive
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000583 Amikacin A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics. A.M.K,Amikacin Sulfate,Amikacina Medical,Amikacina Normon,Amikafur,Amikalem,Amikason's,Amikayect,Amikin,Amiklin,Amukin,BB-K 8,BB-K8,Biclin,Biklin,Gamikal,Kanbine,Oprad,Yectamid,BB K 8,BB K8,BBK 8,BBK8,Medical, Amikacina,Normon, Amikacina,Sulfate, Amikacin
D000617 Aminoglycosides Glycosylated compounds in which there is an amino substituent on the glycoside. Some of them are clinically important ANTIBIOTICS. Aminoglycoside
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases

Related Publications

M E Plaut, and J J Schentag, and W J Jusko
Specificity of renal tubular damage criteria for aminoglycoside nephrotoxicity in critically ill patients.
October 1983, Journal of clinical pharmacology,
M E Plaut, and J J Schentag, and W J Jusko
Suboptimal aminoglycoside dosing in critically ill patients.
December 2008, Therapeutic drug monitoring,
M E Plaut, and J J Schentag, and W J Jusko
Variability in aminoglycoside pharmacokinetics in critically ill surgical patients.
April 1988, Critical care medicine,
M E Plaut, and J J Schentag, and W J Jusko
Comment: once-daily aminoglycoside dosing in critically ill patients.
October 1998, The Annals of pharmacotherapy,
M E Plaut, and J J Schentag, and W J Jusko
Predicting aminoglycoside dosage in critically ill patients with sepsis.
April 1987, Clinical pharmacy,
M E Plaut, and J J Schentag, and W J Jusko
Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis.
February 1987, Clinical pharmacy,
M E Plaut, and J J Schentag, and W J Jusko
Nephrotoxicity associated with intravenous colistin in critically ill patients.
December 2011, Pharmacotherapy,
M E Plaut, and J J Schentag, and W J Jusko
Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients.
November 1987, Antimicrobial agents and chemotherapy,
M E Plaut, and J J Schentag, and W J Jusko
Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients.
January 1986, Journal of clinical pharmacology,
M E Plaut, and J J Schentag, and W J Jusko
Intrapatient variation of aminoglycoside pharmacokinetics in critically ill surgery patients.
March 1988, Clinical pharmacy,
Copied contents to your clipboard!